Development of masked therapeutic antibodies to limit off-target effects

US10357571B2 · kind B2 · utility

Assignees

• Thomas Jefferson University · US
• City of Hope · US

Inventors

• John C. Williams · Duarte, US
• Cindy Zer · Duarte, US
• Kendra N. Avery · Pasadena, US
• Ulrich Rodeck · Philadelphia, US
• Joshua M. Donaldson · Chambersburg, US
• Csaba Kari · Rancho Cordova, US

Key dates

• Filing date: Nov 23, 2015
• Grant date: Jul 23, 2019
• Expiry date: Feb 3, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.